Q2 Earnings Estimate for LEXX Issued By Zacks Small Cap

Lexaria Bioscience Corp. (NASDAQ:LEXX) – Stock analysts at Zacks Small Cap issued their Q2 2025 earnings estimates for Lexaria Bioscience in a research report issued to clients and investors on Tuesday, January 28th. Zacks Small Cap analyst J. Vandermosten forecasts that the company will post earnings of ($0.14) per share for the quarter. The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.59) per share. Zacks Small Cap also issued estimates for Lexaria Bioscience’s Q3 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.57) EPS and FY2026 earnings at ($0.45) EPS.

Lexaria Bioscience (NASDAQ:LEXX) last released its quarterly earnings results on Friday, January 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). Lexaria Bioscience had a negative return on equity of 88.88% and a negative net margin of 1,473.04%.

Separately, HC Wainwright cut their target price on shares of Lexaria Bioscience from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, January 24th.

Lexaria Bioscience Price Performance

Shares of NASDAQ:LEXX opened at $1.77 on Thursday. The company has a market capitalization of $31.07 million, a P/E ratio of -3.54 and a beta of 0.98. The firm’s 50 day simple moving average is $2.13 and its two-hundred day simple moving average is $2.69. Lexaria Bioscience has a 1-year low of $1.43 and a 1-year high of $6.85.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC grew its stake in Lexaria Bioscience by 31.0% in the 3rd quarter. Geode Capital Management LLC now owns 150,391 shares of the company’s stock valued at $459,000 after acquiring an additional 35,608 shares during the period. Renaissance Technologies LLC acquired a new stake in Lexaria Bioscience in the 2nd quarter valued at about $63,000. HighTower Advisors LLC acquired a new position in Lexaria Bioscience during the third quarter worth $40,000. Byrne Asset Management LLC grew its holdings in shares of Lexaria Bioscience by 132.1% in the fourth quarter. Byrne Asset Management LLC now owns 13,000 shares of the company’s stock valued at $27,000 after purchasing an additional 7,400 shares during the period. Finally, XTX Topco Ltd raised its position in shares of Lexaria Bioscience by 47.8% during the 3rd quarter. XTX Topco Ltd now owns 18,626 shares of the company’s stock valued at $57,000 after buying an additional 6,024 shares during the period. Hedge funds and other institutional investors own 13.06% of the company’s stock.

Insider Buying and Selling at Lexaria Bioscience

In related news, CEO Richard Christopher bought 22,828 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were bought at an average price of $2.24 per share, with a total value of $51,134.72. Following the transaction, the chief executive officer now owns 22,828 shares in the company, valued at approximately $51,134.72. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 26.40% of the stock is owned by corporate insiders.

About Lexaria Bioscience

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.